Insertable Cardiac Monitor Helps Detect Infrequent Arrhythmias
By HospiMedica International staff writers Posted on 29 Apr 2016 |
Image: The BioMonitor 2-AF insertable cardiac remote monitor (Photo courtesy of Biotronik).
A new remote cardiac monitor provides physicians with the ability to accurately detect and diagnose atrial fibrillation (AF), ventricular tachycardia (VT), and syncope.
The Biotronik (Berlin, Germany) BioMonitor 2-AFis an insertable cardiac remote monitor designed for highly accurate and reliable continuous detection of cardiac electrical events. It is available in two versions, the first specialized for the detection of AF, and the other designed to help diagnosis in unexplained syncope and VT. The device provides highly specific rhythm discrimination and continuous transmission of patient data, allowing a clear and timely view of clinically relevant events.
The BioMonitor 2-AF is inserted subcutaneously through a minimally invasive procedure under local anesthesia in a process that usually takes under two minutes, with a flexible antenna and a range of positioning options toadapt easily to a patient’s anatomy. The device provides a high sensing amplitude to guarantee reporting accuracy, and also features ProMRI technology, which ensures patients have access to both 1.5T and 3.0T full-body magnetic resonance imaging (MRI) scans. It can also be used to monitor atrial events in patients who have undergone ablation procedures.
“BioMonitor 2 simplifies the diagnosis of inconsistent and potentially life-threatening arrhythmias for physicians and patients,” said Marlou Janssen, President of Biotronik. “The easy insertion process and continuous wireless monitoring help ensure patient compliance, while providing accurate data for physician diagnosis. This innovative technology further underscores Biotronik’s commitment to delivering cardiac technology that safely and effectively enables patients to live life to the fullest.”
“The clinical and economic burdens of stroke are high and continue to grow. Prevention is necessary, yet more than 35% of strokes are cryptogenic and occur with no known cause,” said Mark Richards, PhD, MD, arrhythmia and cryptogenic stroke programs director at the Promedica Heart & Vascular Institute (Toledo, OH, USA). “New diagnostic technologies, such as those found in the BioMonitor 2, can help manage these high-risk patients more effectively and efficiently.”
Related Links:
Biotronik
The Biotronik (Berlin, Germany) BioMonitor 2-AFis an insertable cardiac remote monitor designed for highly accurate and reliable continuous detection of cardiac electrical events. It is available in two versions, the first specialized for the detection of AF, and the other designed to help diagnosis in unexplained syncope and VT. The device provides highly specific rhythm discrimination and continuous transmission of patient data, allowing a clear and timely view of clinically relevant events.
The BioMonitor 2-AF is inserted subcutaneously through a minimally invasive procedure under local anesthesia in a process that usually takes under two minutes, with a flexible antenna and a range of positioning options toadapt easily to a patient’s anatomy. The device provides a high sensing amplitude to guarantee reporting accuracy, and also features ProMRI technology, which ensures patients have access to both 1.5T and 3.0T full-body magnetic resonance imaging (MRI) scans. It can also be used to monitor atrial events in patients who have undergone ablation procedures.
“BioMonitor 2 simplifies the diagnosis of inconsistent and potentially life-threatening arrhythmias for physicians and patients,” said Marlou Janssen, President of Biotronik. “The easy insertion process and continuous wireless monitoring help ensure patient compliance, while providing accurate data for physician diagnosis. This innovative technology further underscores Biotronik’s commitment to delivering cardiac technology that safely and effectively enables patients to live life to the fullest.”
“The clinical and economic burdens of stroke are high and continue to grow. Prevention is necessary, yet more than 35% of strokes are cryptogenic and occur with no known cause,” said Mark Richards, PhD, MD, arrhythmia and cryptogenic stroke programs director at the Promedica Heart & Vascular Institute (Toledo, OH, USA). “New diagnostic technologies, such as those found in the BioMonitor 2, can help manage these high-risk patients more effectively and efficiently.”
Related Links:
Biotronik
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure